{"id":"NCT01364649","sponsor":"Takeda","briefTitle":"Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2011-06-02","resultsPosted":"2014-10-09","lastUpdate":"2014-10-09"},"enrollment":447,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Treatment Outcome"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004"]},{"type":"DRUG","name":"Escitalopram","otherNames":["Lexapro"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vortioxetine","type":"EXPERIMENTAL"},{"label":"Escitalopram","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.","primaryOutcome":{"measure":"Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Vortioxetine","deltaMin":8.8,"sd":0.64},{"arm":"Escitalopram","deltaMin":6.6,"sd":0.64}],"pValues":[{"comp":"OG000 vs OG001","p":"0.013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States","Canada"]},"refs":{"pmids":["31010445"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":224},"commonTop":["Nausea","Headache","Dizziness","Irritability","Fatigue"]}}